Recovering the raw data behind a non-parametric survival curve

[1]  J. Hanley,et al.  Measuring the Mortality Impact of Breast Cancer Screening , 2013, Canadian Journal of Public Health.

[2]  J. Gohagan,et al.  Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. , 2012, Journal of the National Cancer Institute.

[3]  M. Fey,et al.  Marriage risk of cancer research fellows , 2011, The Lancet.

[4]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[5]  Karen A Gelmon,et al.  Exemestane for breast-cancer prevention in postmenopausal women. , 2011, The New England journal of medicine.

[6]  J. Jansen.  Network meta-analysis of survival data with fractional polynomials , 2011, BMC medical research methodology.

[7]  Elena Losina,et al.  Evaluation of exposure-specific risks from two independent samples: A simulation study , 2011, BMC medical research methodology.

[8]  C. Alexopoulou,et al.  Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  James A Hartley.  Mortality reductions produced by sustained prostate cancer screening have been underestimated , 2010, Journal of medical screening.

[10]  Z. Philips,et al.  Network meta‐analysis of parametric survival curves , 2010, Research synthesis methods.

[11]  Paul Murrell,et al.  Importing Vector Graphics: The grImport Package for R , 2009 .

[12]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[13]  M. Sydes,et al.  Practical methods for incorporating summary time-to-event data into meta-analysis , 2007, Trials.

[14]  J. Hanley.  Analysis of Mortality Data From Cancer Screening Studies: Looking in the Right Window , 2005, Epidemiology.

[15]  Paula R Williamson,et al.  Aggregate data meta‐analysis with time‐to‐event outcomes , 2002, Statistics in medicine.

[16]  L. Collette,et al.  Estimating Number of Events from the Kaplan–Meier Curve for Incorporation in a Literature‐Based Meta‐Analysis: What You Don't See You Can't Get! , 2000, Biometrics.

[17]  George A. Wells,et al.  An Assessment of Methods to Combine Published Survival Curves , 2000, Medical decision making : an international journal of the Society for Medical Decision Making.

[18]  M. Parmar,et al.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.

[19]  R. Troughton,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[20]  C. Lawton,et al.  Screening and Prostate-Cancer Mortality in a Randomized European Study , 2010 .

[21]  G. Moneta,et al.  Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein , 2009 .

[22]  Paula R. Williamson,et al.  The value of the aggregate data approach in meta‐analysis with time‐to‐event outcomes , 2001 .

[23]  H. L. Le Roy,et al.  Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability; Vol. IV , 1969 .

[24]  B. Efron.  The two sample problem with censored data , 1967 .

[25]  Wei-Mou Zheng,et al.  T E C H N I C a L a D V a N C E Open Access , 2022 .